Phibro Animal Health (PAHC) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Takeda Pharmaceutical (TAK) has outperformed Phibro Animal Health (PAHC) over the past year, gaining 29.4% versus a gain of 0.8%. Over five years, PAHC leads with a +71.6% price change compared with +31.3% for TAK. Takeda Pharmaceutical is the larger company by market cap ($59.75 billion vs $1.58 billion), about 37.9 times the size.
On valuation, Phibro Animal Health trades at a lower forward P/E (10.1x vs 35.3x for Takeda Pharmaceutical). Takeda Pharmaceutical offers the higher dividend yield (1069.23% vs 1.24%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PAHC | TAK |
|---|---|---|
| Share price | $38.82 | $18.71 |
| Market cap | $1.58B | $59.75B |
| 1-day change | +3.80% | +1.00% |
| YTD return | +0.11% | +18.79% |
| 1-year return | +0.78% | +29.42% |
| 5-year return | +71.56% | +31.35% |
| P/E ratio (TTM) | 15.98 | — |
| Forward P/E | 10.10 | 35.29 |
| EPS (TTM) | $2.43 | $-0.34 |
| Dividend yield | 1.24% | 1069.23% |
| Annual dividend | $0.48 | $200.00 |
| Revenue (latest FY) | $1.52B | — |
| Revenue growth (YoY) | +17.12% | — |
| Net income (latest FY) | $99.72M | — |
| Gross margin | 33.76% | — |
| Operating margin | 12.81% | — |
| Net margin | 6.57% | — |
| 52-week high | $60.08 | $19.10 |
| 52-week low | $28.25 | $12.99 |
| Distance from 52-week high | -35.39% | -2.07% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +13.34% | +17.40% |
| Average volume | 236.19K | 3.04M |
| Shares outstanding | 21.11M | 3.19B |
| Employees | 2,605 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Takeda Pharmaceutical is about 37.9 times larger than Phibro Animal Health by market value ($59.75B vs $1.58B).
- TAK has outperformed PAHC by 28.6 percentage points over the past year.
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (1069.23% vs 1.24%).
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
PAHC vs TAK FAQ
Which is bigger, Phibro Animal Health or Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) is larger, with a market capitalization of $59.75B compared with $1.58B for Phibro Animal Health (PAHC).
Which stock has performed better over the past year, PAHC or TAK?
TAK returned +29.42% over the past 12 months, compared with +0.78% for PAHC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Phibro Animal Health or Takeda Pharmaceutical?
Takeda Pharmaceutical has the higher yield at 1069.23%, compared with 1.24% for Phibro Animal Health.
Are Phibro Animal Health and Takeda Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.